Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor protein p63 regulated 1 (TPRG1) is a protein involved in the cellular inflammatory response, proliferation, and migration, particularly in the context of bladder diseases such as cystitis glandularis and potentially bladder adenocarcinoma. Its expression is upregulated in inflamed and tumorous tissues. Functional studies indicate that silencing TPRG1 can suppress inflammation and pathological proliferation via the NF-κB/cyclooxygenase-2/prostaglandin E2 (COX-2/PGE2) axis, making it of interest both as a possible therapeutic target and a disease biomarker. TPRG1 itself is regulated by the transcription factor p63 and may play distinct roles in disease progression and recurrence. Notes: - TPRG1 is distinct from “tumor protein p63” (TP63/p63), which is a well-characterized transcription factor; TPRG1 is a downstream protein regulated by p63. - There is currently no standardized list of drugs directly targeting TPRG1, nor is it a member of the better-known molecular target classes (e.g., receptor, enzyme). - No major safety issues are reported for targeting TPRG1 directly as of this writing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor protein p63 regulated 1 (TPRG1).